Paroxetine: Nursing Drug Guide, Discontinuation Syndrome & NCLEX Review

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) supplied as immediate-release tablets (10 mg, 20 mg, 30 mg, 40 mg), extended-release tablets (Paxil CR), and oral suspension (10 mg/5 mL—not currently marketed in some regions). Verify strength, formulation (IR vs ER), and taper plan on every administration pass.

Common U.S. brand examples include Paxil (immediate-release tablets), Paxil CR (extended-release), and PEXEVA. A low-dose paroxetine product (Brisdelle) is labeled separately for vasomotor symptoms of menopause—do not interchange with psychiatric-dose products without prescriber and pharmacy verification.

• Tablet strengths (IR): 10 mg, 20 mg, 30 mg, 40 mg per prescribing information
• Look-alike name: Tall-man lettering PARoxetine appears on some labels to reduce confusion with fluoxetine and other -oxetine SSRIs
• Not interchangeable: Do not substitute Paxil CR for Paxil immediate-release or Brisdelle without prescriber and pharmacy verification—absorption and taper schedules differ

Paroxetine is indicated in adults for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder (SAD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). Screen for bipolar disorder before starting antidepressant monotherapy—untreated depression carries suicide risk, but antidepressant monotherapy may precipitate mania in susceptible patients.

↔On a small screen, swipe or scroll sideways to see the full table.

Although the exact mechanism is unknown, paroxetine is presumed to work by potentiating serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT). Studies at clinically relevant doses demonstrate blockade of serotonin uptake into human platelets.

Paroxetine is also a potent CYP2D6 inhibitor, which matters at the bedside when patients take tamoxifen, certain beta-blockers, or other CYP2D6-metabolized drugs. Its relatively short elimination half-life (~21 hours) means drug levels fall faster after missed doses than with fluoxetine—this pharmacokinetic profile contributes to the prominence of discontinuation syndrome when therapy stops abruptly or adherence lapses.

Dosing depends on indication, age, renal/hepatic function, and formulation (immediate-release vs extended-release). Most adult regimens are given as a single daily dose in the morning, with or without food. When discontinuing paroxetine, gradually reduce the dosage rather than stopping abruptly whenever possible.

Other labeled indications

↔On a small screen, swipe or scroll sideways to see the full table.

MAOI switching (critical): At least 14 days between discontinuation of an MAOI and initiation of paroxetine, and at least 14 days after stopping paroxetine before starting an MAOI antidepressant.

Discontinuation taper (example from GAD/PTSD trials): Gradual decreases of 10 mg/day at weekly intervals, followed by 1 week at 20 mg/day before stopping—institutional protocols and prescriber orders may vary.

Missed dose: Do not double doses. If a patient misses multiple doses, do not resume the full prior dose without prescriber/pharmacy review—discontinuation symptoms may emerge and restarting too aggressively can cause adverse effects.

Pretreatment checks

• Perform medication reconciliation for MAOIs, linezolid, IV methylene blue, other SSRIs/SNRIs, tramadol, triptans, and duplicate paroxetine products (IR vs CR)
• Confirm at least 14 days since any MAOI before first paroxetine dose; confirm taper plan if switching away from paroxetine
• Assess mood, suicidality, sleep, and activation symptoms (agitation, insomnia)—especially in patients age 24 years and younger
• Review seizure history and drugs that prolong QT (pimozide and thioridazine are contraindicated with paroxetine)
• Check recent sodium when available—SSRIs may cause hyponatremia/SIADH; trend sodium if confusion, headache, or falls develop

Contraindications

• MAOIs (including linezolid and IV methylene blue) with paroxetine or within 14 days of stopping an MAOI
• Paroxetine within 14 days of stopping an MAOI antidepressant
• Concomitant thioridazine or pimozide (QT prolongation risk; paroxetine inhibits CYP2D6)
• Known hypersensitivity to paroxetine (anaphylaxis, angioedema, Stevens-Johnson syndrome reported)

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablets (10 mg, 20 mg, 30 mg, 40 mg immediate-release) or extended-release tablets (Paxil CR). Oral suspension 10 mg/5 mL—shake well before administration when used. May be taken with or without food; food may increase peak concentration but is not clinically significant for most patients.

• Give as a single daily morning dose unless prescriber orders otherwise
• Swallow tablets whole—do not crush or chew extended-release (Paxil CR) tablets
• Verify IR vs CR formulation and strength before administration—40 mg green IR tablet vs CR strengths are a common mix-up risk
• When patient self-discontinues or misses doses, assess for discontinuation syndrome before simply restarting the prior dose
• Document adherence; even short lapses can trigger withdrawal-type symptoms with paroxetine

• Gradual improvement in depressive and anxiety symptoms over 4 or more weeks—early partial response is common
• Reduced panic attack frequency after panic-disorder titration to therapeutic dose
• Decreased obsessive-compulsive symptoms with consistent daily dosing over several weeks—do not stop early when symptoms improve without a taper plan
• Stable mood and behavior without new suicidality, mania, or discontinuation symptoms when doses are taken consistently
• When stopping therapy, gradual dose reduction minimizes discontinuation syndrome—abrupt improvement in mood does not mean the drug can be stopped suddenly

Discontinuation syndrome and serotonin syndrome can look like medication failure or anxiety relapse—clarify timing of last dose and any new serotonergic drugs. Discontinue paroxetine and concomitant serotonergic agents when serotonin syndrome is suspected and initiate supportive treatment per protocol.

• Electric-shock sensations, dizziness, nausea, irritability, or insomnia after missed doses or self-discontinuation—do not restart full dose without prescriber review
• Mental status changes—agitation, hallucinations, delirium, or coma—especially after new tramadol, triptan, or linezolid
• Autonomic instability—tachycardia, labile blood pressure, hyperthermia, diaphoresis
• Neuromuscular hyperactivity—tremor, rigidity, myoclonus, hyperreflexia, incoordination
• New or worsening suicidal ideation, self-harm behaviors, or sudden behavioral changes in young adults
• Mania/hypomania, racing thoughts, or decreased need for sleep—hold and notify prescriber
• Severe rash, angioedema, or systemic allergic signs—stop permanently unless allergy service approves rechallenge
• Symptomatic hyponatremia—headache, confusion, weakness, unsteadiness; severe cases may include seizure or coma

↔On a small screen, swipe or scroll sideways to see the full table.

Prescribing information does not list a specific reversal agent for paroxetine overdose. Management is supportive, with activated charcoal considered in patients who present early after ingestion. Co-ingestion with other serotonergic drugs increases serotonin syndrome risk.

Reported overdose findings

• Seizures (may be delayed) and altered mental status including coma
• Cardiovascular toxicity (may be delayed)—QRS and QTc prolongation; hypertension most common; hypotension possible with co-ingestants including alcohol
• Serotonin syndrome—especially with multiple pro-serotonergic drugs

Supportive care

• Airway, breathing, circulation; cardiac monitoring including ECG for delayed QT and arrhythmias
• Consider gastrointestinal decontamination with activated charcoal when presentation is early
• Treat seizures and hyperthermia per emergency protocol
• Discontinue paroxetine and other serotonergic agents when toxicity is suspected

• PARoxetine vs FLUoxetine vs fluvoxamine—all are SSRIs with different half-lives and taper rules; verify generic name on MAR
• Paxil vs Paxil CR—immediate-release vs extended-release; not interchangeable without prescriber and pharmacy approval
• Strength mix-ups—10 mg, 20 mg, 30 mg, 40 mg IR tablets; 40 mg green tablet is a high-strength unit
• Duplicate SSRI therapy—home paroxetine plus newly ordered sertraline or escitalopram is a common reconciliation error
• Brisdelle vs Paxil—both contain paroxetine but are labeled for different indications and doses—do not interchange
• MAOI / linezolid orders—linezolid is an MAOI-class interaction; treat as contraindicated unless documented specialist plan with 14-day washout

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Mood, suicidality, anxiety, sleep, and activation symptoms at each contact during the first months and after dose changes
• Discontinuation syndrome cues when doses are missed, held, or stopped—dizziness, electric-shock sensations, nausea, irritability, insomnia
• Signs of serotonin syndrome when serotonergic drugs are added—mental status, temperature, heart rate, blood pressure, tremor, reflexes via neurological assessment
• Sodium and volume status in older adults, diuretic users, or patients with confusion, headache, or falls
• Bleeding in patients on anticoagulants or antiplatelet therapy
• Mania/hypomania symptoms when treating depression—sleep reduction, grandiosity, impulsivity

Document

• Dose, formulation (IR vs CR), time, indication, and patient response including behavioral changes reported by family
• Adherence and any missed doses—document prescriber/pharmacy notification when restart or taper is needed
• MAOI/linezolid screening and 14-day washout verification when antidepressants are switched
• Education on never stopping abruptly and when to seek urgent help for discontinuation or serotonin syndrome symptoms
• Hold events, prescriber/pharmacist notification, and follow-up monitoring plan

• Take as directed every day in the morning unless prescriber specifies otherwise—full benefit may take several weeks
• Do not stop paroxetine suddenly even if you feel better—ask for a taper plan; missed doses can cause dizziness, electric-shock feelings, nausea, and irritability
• Do not start MAO inhibitor diets, linezolid, or St. John’s wort without prescriber approval; tell all clinicians you take paroxetine before new medicines
• Report worsening depression, suicidal thoughts, agitation, or unusual behavior immediately—especially if you are a young adult
• Seek urgent care for high fever with agitation, muscle rigidity, and fast heartbeat—possible serotonin syndrome
• Contact local poison control or toxicology services per your facility’s overdose guidance if overdose is suspected

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for paroxetine with a tabbed outpatient case (MAR, labs, vitals, nursing notes), then work through priority action, discontinuation-syndrome cue recognition, trend interpretation after a taper starts, documentation cloze, suicidality judgment, and matrix urgency with Expected / Concerning / Urgent escalation—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.